For Immediate Release
Oak Brook, IL – The June issue of SLAS Discovery features a special collection of research reviews and perspectives curated by the journal’s Editorial Board.
In this issue, Guest Editors Joseph G. McGivern, Ph.D. (Amgen Research, United States) and Mei Ding, Ph.D. (AstraZeneca, Sweden) present three original research papers and one review that reflect the recent advances and continuing challenges in the development and application of assay technologies that are applicable to drug discovery for ion channel targets. These specially selected papers show that while there is no universal ion channel screening strategy that satisfy all needs, researchers must understand the advantages and disadvantages of different screening technologies and choose those that are fit for purpose when designing and executing assays for primary and secondary screening, selectivity and safety profiling.
Articles in the special collection include:
Additional articles and reviews within the June issue include:
Access to June’s SLAS Discovery issue is available at https://journals.sagepub.com/toc/jbxb/25/5 through July 20. For more information about SLAS and its journals, visit www.slas.org/publications/slas-discovery/.
SLAS (Society for Laboratory Automation and Screening) is an international community of 16,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS Discovery: Advancing the Science of Drug Discovery, 2018 Impact Factor 2.192. Editor-in-Chief Robert M. Campbell, Ph.D., Twentyeight-seven Therapeutics, Boston, MA (USA).
SLAS Technology: Translating Life Sciences Innovation, 2018 Impact Factor 2.048. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).
Director of Marketing Communications
Telephone: +1.630.256.7527, ext. 103